Trial reportInternational journal of cosmetic science2025
Evaluation of the effect of an extract of Sphingomonas xenophaga present in a Thermal Spring Water in the management of sensitive skin associated with cutaneous vascular disorder.
Trial report in International journal of cosmetic science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of the effect of an extract of Sphingomonas xenophaga present in a Thermal Spring Water in the management of sensitive skin associated with cutaneous vascular disorder.International journal of cosmetic science · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveLa Roche Posay Thermal Spring Water (LRP TSW), which contains specific minerals and possesses a unique microbial composition, has proven anti-oxidant, anti-inflammatory, pre- and post-biotic properties and an ability to improve skin barrier function. Our objective was to confirm the effectiveness of a biomass isolated from LRP TSW on inflammatory and vascular parameters in sensitive skin.
methodsA fully characterized strain of Sphingomonas xenophaga was isolated from LRP TSW. An industrial fermentation process was developed to obtain a reproducible biomass (the 'ferment extract') in order to evaluate its effect on skin parameters in vitro and in vivo. Inhibition of pre-kallikrein activity, which converts pro-bradykinin into inflammatory vasoactive bradykinin, by the ferment extract was determined in vitro. In vivo, the effect of a 4-week, twice-daily application of a 2% ferment extract cream formulation on vascular disorders was investigated in a randomized study including 86 Caucasian female subjects presenting permanent redness and vascular disorder on the face in comparison to the cream vehicle.
resultsThe ferment extract inhibited in a dose-dependent manner pre-kallikrein activity in vitro, inducing 46% and 97% inhibition at concentrations of 0.4% and 0.5%, respectively. In vivo after 28 days of twice-daily applications of the ferment extract and vehicle, both treatments induced a significant decrease in vascular disorder as evaluated by clinical scoring (Dermascore® device with cross-polarized light). The mean decrease in vascular disorder score from baseline was significantly greater (p < 0.05) in the ferment extract group (-0.36) when compared to vehicle (-0.18). In addition, 60% of subjects in the group treated with the formulated ferment extract had a decreased score compared to 33% for the group treated with the vehicle.
conclusionInhibition of the production of inflammatory vasoactive bradykinin by the ferment extract observed in vitro is in line with the anti-inflammatory effects of the formulated extract as shown in subjects with facial vascular disorder. The results in this study suggest that this ferment extract is a potentially new active ingredient that could be used either alone or in combination with other soothing agents to target skin inflammatory pathways and to improve skin vascular disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.